|
Luminal A Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In postmenopausal women, Luminal A (OR 2.35, 95% CI 2.01-2.75), Luminal B HER2 negative (OR 1.81, 95% CI 1.46-2.25) and triple-negative subtype (OR 2.25, 95% CI 1.85-2.72) showed higher risk of breast cancer in obese II women.
|
31628583 |
2020 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low protein expression was associated with a higher relapse rate in patients with Luminal A and HER2-positive tumours, but not triple-negative tumours.
|
31025094 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ninety five (52.5%) patients experienced axillary downstaging after PST, by molecular subtype 15% (3/20) in Luminal A, 46.4% (45/97) in Luminal B, 90.9% (20/22) in HER2+ and 70.3% (26/37) in triple negative breast tumours.
|
30744944 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among molecular subtypes, higher intake of total fruits and vegetables (HR per 2 additional servings/day as a continuous variable) was most strongly associated with lower risk of human epidermal growth factor receptor 2 (HER2)-enriched (HR = 0.79, 95%CI = 0.67-0.93), basal-like (HR = 0.84, 95%CI = 0.72-0.97) and luminal A (HR = 0.94, 95%CI = 0.89-0.99), but not with luminal B tumors (p<sub>heterogeneity</sub> = 0.03).
|
29978479 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the PAM50-ISs (Luminal A, Luminal B, HER2-enriched, and Basal-like), GE-Luminal A showed the lowest pCR rate (1.9%), and multivariate analysis revealed that GE-Luminal A was a significant (P = 0.031) predictor of non-pCR independently of other clinicopathological parameters, including Ki67, and tumor-infiltrating lymphocytes.
|
30361874 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
When combining both cohorts, worse survival was found for patients with CCND1-amplified tumours in luminal A (HR = 1.68; 95% CI, 1.15-2.46), luminal B (1.37; 1.01-1.86) and ER+/LN-/HER2- (1.66; 1.14-2.41) subgroups.
|
30819233 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Luminal A and B phenotypes presented an upregulation of E-cadherin compared with the HER-2 positive and triple-negative phenotypes (P<0.05).
|
31807173 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
More than 40% of TPBCs were classified as the luminal A intrinsic subtype, with an even lower HER2 expression level.
|
31410192 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mean total external optoacoustic US feature scores of luminal (A and B) breast cancers were higher (9.9 vs 8.8; <i>P</i> < .05) and total internal scores were lower (6.8 vs 7.7; <i>P</i> < .001) than those of triple-negative and human epidermal growth factor receptor 2-positive (HER2+) cancers.
|
31287388 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
microRNA-21 was up-regulated in HER2 positive and Basal-like breast cancer types, while microRNA-206 was up-regulated in Luminal A and B types of breast cancer. microRNA-21 expression negatively correlated with the level of ER and PR but positively correlated with HER2 expression and tumor malignancy, while microRNA-206 showed the opposite trend.
|
31276668 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
6/82 cases were Luminal A-like (7.3%), 42/82 Luminal B-like (HER2-) (51.2%), 12/82 Luminal B-like (HER2+) (14.6%), 4/82 Non Luminal (HER+) (4.9%), 18/82 Triple Negative (ductal) (22%).
|
30927939 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neither quantitative histogram analysis based on ADC maps nor qualitative visual heterogeneity assessment of DWI images was able to significantly differentiate between molecular subtypes, i.e., luminal A versus all other subtypes (luminal B, HER2-enriched, and triple negative) combined, luminal A and B combined versus HER2-enriched and triple negative combined, and triple negative versus all other types combined.
|
31819738 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ki-67 labeling index assessed by immunohistochemical assays has been shown useful in assessing the risk of recurrence for estrogen receptor (ER)-positive HER2-negative breast cancers (BC) and distinguishing Luminal A-like from Luminal B-like tumors.
|
31422497 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 positive and triple negative subtypes had the highest recurrence rates in the second year, while luminal A and B showed a more continuous pattern over time, with lobular tumours recurring more often.
|
30368776 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significantly, acquisition of radioresistance in MCF-7 and ZR-751 cell lines resulted in a loss of expression of both ERα and PgR and an increase in EGFR expression; based on transcriptomic data they changed subtype classification from their parental luminal A to HER2-overexpressing (MCF-7 RR) and normal-like (ZR-751 RR) subtypes, indicating the extent of phenotypic changes and cellular plasticity involved in this process.
|
30987655 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intrinsic subtypes and molecular scores were computed according to published literature and RISK, RS, ROR and EP were compared against each other and to the intrinsic subtypes Luminal A (lumA), Luminal B (lumB), Her2-enriched (Her2↑), Basal-like (basal), and Normal-like (normal) of PAM50.
|
31174485 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elevated levels of CA15-3 ≥ 25 U/mL were found 34 patients (20.5%) in Luminal A, 15 patients (28.3%) in Luminal B<sub>1</sub>, 15 patients (20.3%) in Luminal B<sub>2</sub>, 7 patients (25%) in human epidermal growth factor receptor 2 overexpressed and 9 patients (22.5%) in triple negative groups.
|
30104028 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to compare the differentially expressed genes (DEGs) and biological functions in MCF-7 (luminal A), SK-BR3 (HER2-enriched) and MDA-MB-231 (triple-negative) cells exposed to BPA at an environmentally human-relevant low dose (10<sup>-8</sup> M) for 30 days, by using the approach of RNA sequencing and online informatics tools.
|
31715268 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2-enriched disease) are more immunogenic than others (e.g.Luminal A or B).
|
30922362 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Besides, its expression has been higher in HER2-enriched and basal-like subtypes compared with luminal A.
|
30912122 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LMR was the benign predictor of luminal A and HER-2 overexpression.
|
31016756 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We matched concordant tumor as luminal A and HR+/HER2-, luminal B and HR+/HER2+, HR-/HER2+ and HER2-enriched, and triple-negative breast cancer (TNBC) and normal- or basal-like.
|
30189722 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer tissues of HER2 overexpression and Basal-like were more significant than Luminal A and Luminal B. MIIP was obviously downregulated and IGFBP2 was upregulated in MDA-MB-231, SKBR3 and MCF-7 versus MCF-10A especially in MDA-MB-231.
|
31078343 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The training dataset comprised 91 patients (luminal A, n = 49; luminal B, n = 8; HER2-enriched, n = 11; triple negative, n = 23), while the validation dataset comprised 52 patients from a second institution (luminal A, n = 17; luminal B, n = 17; triple negative, n = 18).
|
31514736 |
2019 |
|
Luminal A Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At 3 years, the HER2 subtype had the highest RFS 100%, compared to 91.1% in luminal A/B, 85.6% in luminal/HER2 and 81.9% in TNBC.
|
28707744 |
2018 |